Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function - Implications for the adoptive immunotherapy of leukaemia

Clinical and Experimental Immunology

Volumn 126, Issue 3, 2001, Pages 403-411

  Orleans Lindsay, J K ^a   Barber, L D ^b   Prentice, H G ^a   Lowdell, M W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Adoptive immunotherapy; Graft versus leukaemia; Tumour induced immunosuppression

Indexed keywords

ALLOANTIGEN; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; APOPTOSIS; ARTICLE; BLAST CELL; CELL LINE; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DAUDI CELL; EXPOSURE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL; MITOGENESIS; MITOSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; STIMULATION; SUPERNATANT; T LYMPHOCYTE;

CELL DIVISION; CYTOTOXICITY, IMMUNOLOGIC; GRAFT VS LEUKEMIA EFFECT; HL-60 CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-2; ISOANTIGENS; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE ACTIVATION; MITOGENS; SUPPRESSOR FACTORS, IMMUNOLOGIC; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0035655572     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01692.x     Document Type: Article

References (44)

1. Graft-versus-leukemia reactions after bone marrow transplantation
2. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
3. The role of T cells in preventing relapse in chronic myelogenous leukemia
4. Bone marrow transplantation for chronic myeloid leukemia in the first chronic phase: Importance of a graft-versus-leukemia effect
5. The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia
6. Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-α treatment
7. Loss of natural killer activity as an indicator of relapse in acute leukaemia
8. Allogeneic MHC-mismatched activated natural killer cells administered after bone marrow transplantation provide a strong graft-versus-leukaemia effect in mice
9. Generation of leukaemia reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukaemia
10. + T-cell line with potent in vivo graft-versus-leukaemia properties
11. Feasibility of immunotherapy of relapsed leukaemia with ex vivo - Generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
12. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumours: Effects of tumor cells and their supernatants on proliferative responses of lymphocytes
13. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer
14. Impaired activation of NFκB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IκBα
15. Differential loss of T cell signalling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions
16. Tumor- induced suppression of T lymphocyte proliferation coincides with inhibition of jaks expression and IL-2 receptor signalling
17. T cells from patients with Hodgkin's disease have a defective T-cell receptor ζ chain expression that is reversible by T cell stimulation with CD3 and CD28
18. T cells infiltrating Non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present
19. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells
20. Characterization of an AML-derived immunomodulatory factor(s) that inhibit T cell activation and the signal transduction pathways involved
21. Suppression of T cell proliferation by AML cells is an early event in G0 to G1 transition involving inhibition of pRB phosphorylation by cyclin d-cdk6/4
22. The HL60 cell line: A model system for studying human myeloid cell differentiation
23. The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C
24. Natural killer cell proliferation is dependent on human serum and markedly increased utilizing an enriched supplemented basal medium
25. Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2 activated NK cells possess additional specific stimulation pathways
26. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma
27. + T lymphocytes in peripheral blood of patients with advanced melanoma
28. Tumor-induced apoptosis in T lymphocytes: Elucidation of intracellular apoptotic events
29. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha
30. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma
31. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation
32. INK4B is a potential effector of TGF-β-induced cell cycle arrest
33. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function
34. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
35. IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma
36. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells
37. How do cytotoxic lymphocytes kill their targets?
38. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
39. Immune cells in the tumor microenvironment
40. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
41. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (Cdks), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs)
42. CML vaccines as a paradigm of the specific immunotherapy of cancer
43. Ex-vivo generation of anti-pre-B leukemia specific autologous cytolytic T cells
44. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: Preclinical studies